SWOG 0204, Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients

To assess efficacy and toxicity of thalidomide/dexamethasone as a pre-transplant induction regimen. To evaluate the immune reconstitution and recovery post-transplant for both first and second transplants

Patients must have newly diagnosed active multiple myeloma requiring treatment as outlined in the protocol. Patients with IgM peaks are not eligible unless there is either >30% bone marrow plasmacytosis or >3 lytic lesions on skeletal survey.

Patients will receive the drug Dexamethasone by mouth on Days 4, days 9-12, and days 17-20. Treatment will be repeated every 35 days for 3 cycles. The next step will be stem cell collection.

Little Rock, Arkansas
Myeloma Institute for Research and Therapy
Matthew Rhoads
mcrhoads@uams.edu
(501) 296-1503 ext. 1757